kode group

Kode Agalimmune

Kode Agalimmune is a special purpose company, set up to commercialise AGI-134, a Gen 2 KIE for human cancer, and alpha(Gal)OV-IO, an oncolytic virus asset acquired with Agalimmune that makes the patient's tumour cells display α-Gal.

Kode Agalimmune programme: Gen 2 Kode Immunoeducer

AGI-134

A Kode Immunoeducer is a membrane-inserting, antibody-recruiting, complement-activating construct with adjuvant-like activity, designed to use the patient's own tumour as the antigen source for in situ vaccination.

Kode Biotech Limited owns Kode Technology and licenses it to KodeRx, Kode Agalimmune and Kode Veterinary Sciences.

AGI-134 is an α-Gal–adipate–lipid construct, designed for anti-Gal antibody binding and classical complement activation. It is the Gen 2 KIE; K5K and Kv9 are Gen 3 KIEs.

Agalimmune licensed Kode Technology in 2015 to develop AGI-134. BioLineRx acquired Agalimmune in 2017 and ran AGI-134's first clinical study. Kode Agalimmune acquired the programme back in 2025.

Stage: Phase 1/2a safety and dose-finding study completed in 38 late-stage human patients.

how Kode Immunoeducers work

Kode Agalimmune Limited

Company
NZ company 7790617
NZBN
9429047750630
Established
November 2024
Directors
Stephen Henry
John O'Toole
Graham Griffiths · LinkedIn ↗
Key patent
WO 2015/170121, oncology use, to about 2035
Technology
Kode Technology licensee

AGI-134 clinical study: first-in-human results

AGI-134's first-in-human study was a Phase 1/2a safety and dose-finding study in 38 patients with late-stage, heavily pre-treated solid tumours, in the UK, Spain and Israel.

Safety endpoint met

No dose-limiting toxicity at any dose. The maximum tolerated dose was not reached, and doses of up to 200 mg were recommended for further study. Side effects were mostly mild to moderate and short-lived; the most common were tiredness and pain at the injection site.

Stable disease in 29%

11 of the 38 patients had stable disease. Seven of them had already failed checkpoint-inhibitor immunotherapy.

Immune activity

Anti-Gal antibodies rose in most patients. T cells and macrophages were found in injected tumours and, in 47% of evaluated patients, in tumours that were not injected.

Sources: ClinicalTrials.gov NCT03593226 · EU Clinical Trials Register 2018-001032-22 · BioLineRx results, 20 December 2022 · Shaw et al. 2019 (preclinical)

AGI-134: how AGI-134 got here

  • 2007 · Dr Uri Galili publishes the concept of injecting natural α-gal glycolipids into tumours to turn them into autologous cancer vaccines: the idea AGI-134 is built on.
  • 2013 · Agalimmune Ltd founded in the United Kingdom to develop an α-Gal cancer immunotherapy.
  • 2015 · Agalimmune licenses Kode Technology from Kode Biotech, and AGI-134 is built on it.
  • 2017 · BioLineRx acquires Agalimmune and runs AGI-134's first clinical study.
  • 2025 · Kode Agalimmune acquires AGI-134 back, with its patent estate.

The AGI-134 oncology-use patent runs to about 2035. Kode Technology itself remains owned by Kode Biotech and licensed to Kode Agalimmune, as it is to the other Kode companies.

Kode Agalimmune: the oncolytic virus programme,
available for trade sale

Kode Agalimmune holds a second asset alongside AGI-134: alpha(Gal)OV-IO, an oncolytic virus programme acquired with Agalimmune. It pursues the same immune concept by a different route, and it is not a Kode Immunoeducer.

How it differs

A Kode Immunoeducer carries the marker itself and inserts it into the tumour cell's membrane. The oncolytic virus instead delivers a gene. The virus infects tumour cells, those cells make the enzyme that builds α-Gal and display it on their own surfaces. So two things happen at once: the tumour is marked with immune-stimulating α-Gal molecules, and it is also being destroyed by the virus, creating highly decorated immune fragments which help the immune system to recognise neo-antigens.

Where it stands

The programme is currently awaiting funding to progress. Its United States patent was granted in 2024 and runs to 2038 (2036 in other countries), with equivalents granted in Europe, Canada, Japan, Korea, India, Israel, Mexico, Russia and Hong Kong.

It is investigational and has not been given to people.

Kode Agalimmune is not developing the programme itself, and the oncolytic virus patent rights are available for acquisition by a third party. If you are interested in acquiring them, please contact us.

Request an info pack

Kode Agalimmune partners: partnering

AGI-134 partnering, research and development enquiries go to Equitable Oncology, an independently governed New Zealand charity.

Become an Equitable Oncology partner

Equitable Oncology coordinates the clinical, scientific and philanthropic partnerships that advance K5K and AGI-134.

Contact Equitable OncologyContact Kode Agalimmune

Independently governed NZ charity CC64930

The Kode Group: multiple companies, one body of science

Kode Agalimmune is one of three Kode spin-out companies developing Kode Immunoeducers.